Investments
186Portfolio Exits
64Funds
9Partners & Customers
1About Bay City Capital
Bay City Capital is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. Its investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of our partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members.

Want to inform investors similar to Bay City Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Bay City Capital News
May 5, 2021
Oculis S.A. , a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. Led by Riad Sherif, MD, CEO, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Proceeds from this financing will advance the company’s late-stage topical Ophthalmic portfolio, including: – Moving OCS-01 into Phase 3 trials in Diabetic Macular Edema (DME) and complete registration studies in the treatment of Inflammation and Pain following Ocular Surgery. – Advancing OCS-02 into Phase 2b trials targeting Dry Eye Disease (DED) and Chronic Anterior Uveitis as a steroid-sparing treatment. OCS-02 is a novel topical anti-TNF alpha antibody fragment, which has demonstrated efficacy and safety in two clinical proof of concept studies in moderate-to-severe DED and Acute Anterior Uveitis. In conjunction with the closing, Vanessa Huang, General Partner at BVCF Management, and Dr. Sylvia He, Managing Partner at Hyfinity Investments are joining the Oculis Board of Directors while Dr. David Weber and Dr. Thorsteinn Loftsson are stepping down. FinSMEs 06/05/2021
Bay City Capital Investments
186 Investments
Bay City Capital has made 186 investments. Their latest investment was in Spinogenix as part of their Series B on August 8, 2023.

Bay City Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/8/2023 | Series B | Spinogenix | $5.2M | Yes | 2 | |
5/5/2021 | Series C | Oculis | $57M | No | 12 | |
3/2/2020 | Series B | Xilio Therapeutics | $100.5M | Yes | 7 | |
3/18/2019 | Series B | |||||
1/4/2019 | Series B - II |
Date | 8/8/2023 | 5/5/2021 | 3/2/2020 | 3/18/2019 | 1/4/2019 |
---|---|---|---|---|---|
Round | Series B | Series C | Series B | Series B | Series B - II |
Company | Spinogenix | Oculis | Xilio Therapeutics | ||
Amount | $5.2M | $57M | $100.5M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 12 | 7 |
Bay City Capital Portfolio Exits
64 Portfolio Exits
Bay City Capital has 64 portfolio exits. Their latest portfolio exit was Oculis on March 03, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/3/2023 | Reverse Merger | 3 | |||
10/22/2021 | IPO | Public | 10 | ||
3/12/2020 | IPO | Public | 1 | ||
Date | 3/3/2023 | 10/22/2021 | 3/12/2020 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 3 | 10 | 1 |
Bay City Capital Fund History
9 Fund Histories
Bay City Capital has 9 funds, including Bay City Bridge LLC.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
2/13/2018 | Bay City Bridge LLC | Multi-Stage Venture Capital | Closed | $2M | 1 |
10/25/2007 | Bay City Capital Fund V LP | ||||
11/22/2005 | Bay City Capital Fund IV LP | ||||
12/31/2000 | Bay City Capital Fund III LP | ||||
12/31/1999 | North American Nutrition and Agribusiness Fund |
Closing Date | 2/13/2018 | 10/25/2007 | 11/22/2005 | 12/31/2000 | 12/31/1999 |
---|---|---|---|---|---|
Fund | Bay City Bridge LLC | Bay City Capital Fund V LP | Bay City Capital Fund IV LP | Bay City Capital Fund III LP | North American Nutrition and Agribusiness Fund |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $2M | ||||
Sources | 1 |
Bay City Capital Partners & Customers
1 Partners and customers
Bay City Capital has 1 strategic partners and customers. Bay City Capital recently partnered with Takeda Pharmaceutical on November 11, 2016.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/9/2016 | Partner | Japan | Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases . | 1 |
Date | 11/9/2016 |
---|---|
Type | Partner |
Business Partner | |
Country | Japan |
News Snippet | Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases . |
Sources | 1 |
Bay City Capital Team
20 Team Members
Bay City Capital has 20 team members, including current Founder, Managing Director, Fred Craves.
Name | Work History | Title | Status |
---|---|---|---|
Fred Craves | Founder, Managing Director | Current | |
Name | Fred Craves | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Director | ||||
Status | Current |